Valuation : Wockhardt Limited

Market Cap 354B 3.71B 3.19B 3.02B 2.74B 5.14B 5.17B 35.92B 13.81B 180B 13.92B 13.62B 569B P/E 2025
-472x
P/E 2026 89.7x
Enterprise Value 370B 3.87B 3.33B 3.16B 2.86B 5.37B 5.4B 37.49B 14.42B 188B 14.53B 14.21B 594B EV / Sales 2025
8.1x
EV / Sales 2026 5.97x
Free-Float
48.98%
Yield 2025 *
-
Yield 2026 -
1 day-1.86%
1 week+4.34%
Current month+15.70%
1 month+17.97%
3 months+12.46%
6 months+67.83%
Current year+50.70%
1 week 2,076.2
Extreme 2076.2
2,272.9
1 month 1,814.4
Extreme 1814.4
2,272.9
Current year 1,086.7
Extreme 1086.7
2,422.3
1 year 1,086.7
Extreme 1086.7
2,422.3
3 years 213.25
Extreme 213.25
2,422.3
5 years 145.15
Extreme 145.15
2,422.3
10 years 145.15
Extreme 145.15
2,422.3
Manager TitleAgeSince
Chief Executive Officer 53 01/04/2009
Director of Finance/CFO - 01/03/2022
Chief Tech/Sci/R&D Officer - 01/05/1998
Director TitleAgeSince
Chairman 83 06/11/2009
Director/Board Member 53 06/11/2009
Director/Board Member 55 01/07/1996
Change 5-day change 1-year change 3-year change Capi.($)
-1.86%+4.34%+43.57%+808.65% 3.71B
-1.13%-3.11%+13.82%+60.66% 46.21B
-1.13%-5.78%+33.26%+108.13% 38.78B
+0.12%-0.08%+7.12%+78.27% 11.68B
-0.53%-1.37%-13.25%+10.18% 11.55B
-0.38%-2.26%+18.18%+139.63% 9.14B
+0.32%-2.26%+23.08%+34.73% 7.3B
+0.17%-0.74%+13.44%+197.13% 7.15B
-1.00%-5.25%+34.34%-19.63% 7.1B
-3.13%-4.30%-44.88%+11.66% 4.97B
Average -0.86%-1.90%+12.87%+142.94% 14.76B
Weighted average by Cap. -0.88%-3.08%+16.75%+94.07%

Financials

2025 2026
Net sales 30.35B 318M 274M 259M 235M 441M 443M 3.08B 1.18B 15.44B 1.19B 1.17B 48.79B 34.62B 362M 312M 296M 268M 503M 505M 3.51B 1.35B 17.61B 1.36B 1.33B 55.66B
Net income -470M -4.92M -4.24M -4.01M -3.64M -6.82M -6.86M -47.67M -18.33M -239M -18.48M -18.07M -756M 2.13B 22.3M 19.21M 18.19M 16.49M 30.93M 31.09M 216M 83.07M 1.08B 83.73M 81.9M 3.42B
Net Debt 14.33B 150M 129M 122M 111M 208M 209M 1.45B 559M 7.29B 563M 551M 23.04B 15.53B 163M 140M 133M 120M 226M 227M 1.58B 606M 7.9B 611M 597M 24.97B
Logo Wockhardt Limited
Wockhardt Limited is a research-based global pharmaceutical and biotech company. The Company is engaged in the pharmaceutical business. It focuses on the unmet need for antibacterial drugs that are effective against the menace of untreatable superbugs. It manufactures and supplies branded and generic finished formulations, as well as intermediate products like active pharmaceutical ingredients (APIs), worldwide. The Company’s products in India include EMROK, MERIWOK, REINVEXIN, ERLISO, METHYCOBAL 500 MCG 15T, METHYCOBAL INJ 1 ML, METHYCOBAL D 10T, HAPID 10C, PROXYFEN NANO GEL, LIVATIRA 500 10T NEW PACK, LIVATIRA INJ 5 ml, GABAWOK NT 100MG 15T, GABAWOK NT 400MG 15T, ETOBRIX 90 MG 10C, ETOBRIX TH 4 10C, ETOBRIX P 10T, GLARZEN 100IU, TERITIDE, GLIMADAY HS, GLIMADAY FORTE-2, GLIMADAY FORTE-1, GLIMADAY FORTE 3, GLIMADAY 2 mg, GLIMADAY 1 mg, MOPADAY FORTE, INOGLA, WEPOX 4000 IU 1ML, MYCORAL M, Val 450, OKERON INJ 100MCG 1ML, DARBOTIN 40, and DARBOTIN 60.
Employees
2,564
Date Price Change Volume
11/09/26 ₹2,179.40 -1.86% 1,109,909
10/09/26 ₹2,220.60 -1.25% 693,525
09/09/26 ₹2,248.80 +1.12% 1,394,874
08/09/26 ₹2,224.00 +0.72% 1,343,981
07/09/26 ₹2,208.00 +5.71% 4,319,658
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BB
  1. Stock Market
  2. Stocks
  3. WOCKPHARMA Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!